Loading...
Market
What will be the regulatory outcome for Oxford University's Marburg virus vaccine by June 30, 2025?
2
Resolution / Starting Odds
Full approval • 25%
Emergency use authorization • 25%
Conditional approval • 25%
No approval • 25%
Official announcements from regulatory bodies such as the FDA, EMA, or WHO
Story
Oxford University Begins Human Testing of Marburg Virus Vaccine on July 12: BBC
Jul 12, 2024, 05:04 AM
Scientists at Oxford University have commenced human testing of a vaccine for the Marburg virus on July 12. This development, reported by BBC, marks a significant step in combating the deadly virus, which has been a concern for global health authorities due to its high mortality rate and potential for outbreaks. The Marburg virus is related to the Ebola virus and causes severe hemorrhagic fever in humans. The vaccine aims to provide immunity and prevent future outbreaks, contributing to global health security.
View original story
Similar markets
Safety concerns resolved • 25%
Further investigation required • 25%
Vaccine trials permanently halted • 25%
Other outcome • 25%
Yes • 50%
No • 50%
Effective • 25%
Moderately Effective • 25%
Ineffective • 25%
Halted • 25%
Yes • 50%
No • 50%
Fast-tracked approval • 25%
Standard approval process • 25%
Request for more data • 25%
Rejection • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Successful • 25%
Partially Successful • 25%
Unsuccessful • 25%
No Results Released • 25%
Hold lifted with no conditions • 25%
Hold lifted with conditions • 25%
Hold extended • 25%
Hold converted to permanent suspension • 25%